Equities

Elite Pharmaceuticals Inc

ELTP:QBB

Elite Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3889
  • Today's Change0.001 / 0.36%
  • Shares traded1.63m
  • 1 Year change+381.79%
  • Beta0.1231
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments7.117.838.54
Total Receivables, Net193.093.06
Total Inventory139.556.74
Prepaid expenses0.521.030.53
Other current assets, total------
Total current assets402219
Property, plant & equipment, net15106.98
Goodwill, net------
Intangibles, net6.346.346.63
Long term investments0.090.020.09
Note receivable - long term------
Other long term assets------
Total assets844135
LIABILITIES
Accounts payable2.712.451.43
Accrued expenses5.715.064.90
Notes payable/short-term debt4.0000
Current portion long-term debt/capital leases0.610.310.35
Other current liabilities, total0.010.010.01
Total current liabilities137.836.69
Total long term debt4.763.561.39
Total debt9.373.871.74
Deferred income tax------
Minority interest------
Other liabilities, total8.260.541.84
Total liabilities26129.93
SHAREHOLDERS EQUITY
Common stock1.071.011.01
Additional paid-in capital173165165
Retained earnings (accumulated deficit)(116)(136)(140)
Treasury stock - common(0.31)(0.31)(0.31)
Unrealized gain (loss)------
Other equity, total------
Total equity582925
Total liabilities & shareholders' equity844135
Total common shares outstanding1,0681,0141,011
Treasury shares - common primary issue0.100.100.10
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.